REFERENCES
  1. AIRTUM, Italian Cancer Figures - Report 2012 Cancer in children and adolescents Epidemiol Prev 2013; 37(1 Suppl 1): 1-296
  2. Ferrari A, Brecht IB, Gatta G, et al. Defining and listing very rare cancers of pediatric age: consensus of the Joint Action on Rare Cancers (JARC) in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Eur J Cancer . 2019; 110: 120-126.
  3. Cordoro KM, Gupta D, Frieden IJ, McCalmont T, Kashani-Sabet M. Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol. 2013; 68: 912–925.
  4. Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma. Pediatrics. 2005; 115 (3): 649-54
  5. Han D, Zager JS, Han G, et al. The unique clinical characteristics of melanoma diagnosed in children. Ann SurgOncol . 2012; 19: 3888–3895.
  6. Spatz A, Ruiter D, Hardmeier T, et al. Melanoma in childhood: an EORTC–MCG multicenter study on the clinico-pathological aspects.Int J Cancer . 1996; 68: 317–324.
  7. Massi D, Tomasini C, Senetta R, et al. Atypical Spitz tumors in patients younger than 18 years. J AmAcad Dermatol. 2015; 72: 37–46.
  8. Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Lancet Oncol . 2016; 17:1248–1260.
  9. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.Lancet . 2015; 386: 444–451.
  10. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med . 2017; 377: 1345–1356.
  11. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med . 2017; 377: 1813–1823.
  12. Indini, Brecht IB, Del Vecchio M, Sultan I, Ferrari A. Cutaneous melanoma in adolescents and young adults. Pediatr Blood Cancer . 2018; 65(11): e27292.
  13. Ferrari A, Bernasconi A, Sironi G, et al. Where Are Adolescents with Soft Tissue Sarcomas Treated? An Italian Nationwide Study on Referrals Based on Hospital Discharge Records. J Adolesc Young Adult Oncol . 2020; 9 (2): 190-195
  14. Ferrari A, Bisogno G, Cecchetto G, et al. Cutaneous melanoma in children and adolescents: the Italian Rare Tumors in Pediatric Age Project Experience. J Pediatr . 2014; 164: 375–382
  15. Wouters MW, Michielin O, Bastiaannet E, et al. ECCO essential requirements for quality cancer care: melanoma. Crit Rev Oncol Hematol . 2018; 122: 164–178.
  16. Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.Lancet Oncol . 2016; 17: 1248–1260.
  17. Chisholm JC, Suvada J, Dunkel IJ, et al. BRIM-P: a phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer . 2018; 65: e26947.
  18. Geoerger B, Bergeron C, Gore L, et al. Phase II study of ipilimumab in adolescentswith unresectable stage III or IV malignant melanoma.Eur J Cancer . 2017; 86: 358–363.
  19. Momper JD, Mulugeta Y, Green DJ, et al. Adolescent dosing and labeling since the Food andDrug Administration Amendments Act of 2007.JAMA Pediatr. 2007; 167: 926–932.